Evaluation of antiviral treatments for recurrent herpes simplex labialis in the dorsal cutaneous guinea pig model.
Recurrent herpes simplex labialis has proved to be a difficult disease to treat. Despite 25 years of clinical research with established antiviral substances, only small benefits from experimental therapies have been demonstrated. Progress has been slow, in part, because of the time-consuming nature of large, patient-initiated clinical trials. The dorsal cutaneous guinea pig model is a rapid and efficient means to identify topical antiviral formulations with clinical promise. The cumulative results of our studies with 19 different test treatments show that 8 were equal in efficacy to 5% acyclovir ointment, one was worse and ten were better. Two of the treatments found to be better than 5% acyclovir ointment have been studied clinically, with limited but encouraging results. Differences between the guinea pig model and the human illness mandate caution in predicting the degree of clinical efficacy from experimental outcomes. An effective and conservative use of the model is to optimize the topical formulation of a single antiviral substance.
Spruance
S L
SL
Department of Medicine, University of Utah School of Medicine, Salt Lake City 84132.
McKeough
M B
MB
D000212:Acyclovir / Q000008:administration & dosage / Q000493:pharmacokinetics; D000287:Administration, Topical; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006560:Herpes Labialis / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000378:metabolism
D000998:Antiviral Agents; D000212:Acyclovir